Related Experiment Video
Updated: May 17, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Posterior reversible encephalopathy syndrome (PRES) after combination chemotherapy for lymphoma
Ambili Ramachandran1, Robin Klein
11Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA 2Department of Internal Medicine, Division of General Medicine, Emory University School of Medicine, Atlanta, GA.
Abstract:
Posterior reversible encephalopathy syndrome (PRES) is a serious neurologic disorder marked by acute neurologic symptoms and classic neuroimaging lesions. It occurs in the setting of certain medications and predisposing clinical conditions. We present a case of PRES in a patient with mantle cell lymphoma treated with systemic and intrathecal chemotherapy. The literature suggests a propensity for PRES to arise from the combination of malignancy, intensive induction chemotherapy, and intrathecal administration. PRES is an uncommon and underappreciated complication of certain chemotherapy regimens. The risk of PRES in this setting needs to be considered in managing patients with hematologic malignancies.
Related Concept Videos
Hepatic Encephalopathy
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
